Catalyst Calendar

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer). Pixclara addresses a significant unmet need helping physicians differentiate

Notification of cessation of securities - TLX

Notification regarding unquoted securities - TLX

Application for quotation of securities - TLX

FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

Change in substantial holding

Appendix 3Y Change in Director Interest-D Gill

Application for quotation of securities - TLX

Grant of waivers of Listing Rule 7.3.4

Telix + ITM Investor Presentation

Telix and ITM Join Forces to Create Radiopharma Powerhouse

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

Application for quotation of securities - TLX

FDA Approves Telix Brain Cancer Imaging Drug Pixclara

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients. Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden

Telix Completes Enrollment in Phase 3 BiPASS Study

Telix Appoints David Gill as Chair

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

MELBOURNE, Australia and INDIANAPOLIS, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the period ended June 30, 2026. H1 2026 key results Group performance 1: Double-digit revenue growth and gross margin

Telix HY26 Results Presentation

Telix HY26 Results Announcement

Telix HY26 Appendix 4D and Interim Report

Telix to Host R&D Day in New York City on September 22, 2026

MELBOURNE, Australia and INDIANAPOLIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will host a Research and Development (R&D) Day on Tuesday, September 22, 2026, from 8:30 a.m. to 12:30 p.m. EDT in New York City.

Telix H1 2026 Results - Investor Webcast Notification

Change in substantial holding

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

Peer-reviewed publication of ProstACT SELECT 1 results confirm the utility of 68 Ga (gallium)-PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach 2. Consistent with previously reported results 3, the publication highlights TLX591-Tx’s clinical differentiation and

Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

First patient dosed in Phase 3 LUTEON 1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC). LUTEON is the first Phase 3 study of a CAIX 2 -targeted radiopharmaceutical therapy in ccRCC. MELBOURNE (Australia) and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE)

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

First patients dosed in OPTIMAL-e 1 Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent’s Hospital Sydney. OPTIMAL-e will evaluate TLX597-Tx in earlier prostate cancer treatment setting, building on the OPTIMAL-PSMA 2 study which recently completed